[A23-71] Dapagliflozin (heart failure with LVEF > 40 %) – Addendum to Commission A23-11
Last updated 17.08.2023
Project no.:
A23-71
Commission:
Commission awarded on 11.07.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Heart and circulation
Indication:
Adults with symptomatic chronic heart failure with left ventricular ejection fraction > 40%
Result of dossier assessment:
Unchanged after addendum
- Without type 2 diabetes mellitus (T2DM) and without chronic kidney disease (CKD) or with/without T2DM and with CKD: hint of non-quantifiable added benefit
- with T2DM and without CKD: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A23-11 | Dapagliflozin (heart failure with preserved ejection fraction) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2023-08-17 A G-BA decision was published.